QPS India Successfully Completes Week-Long US FDA Regulatory Inspection
Article content
NEWARK, Del. — QPS India, a subsidiary of QPS Holdings, LLC (QPS), a GLP/GCP-compliant global full-service Contract Research Organization, has achieved another significant milestone by successfully completing an unscheduled inspection by the US Food and Drug Administration (FDA) from the 21st to the 25th of April 2025. The inspection was a systems & processes audit resulting in the site approval for all studies conducted at QPS India and submitted by sponsors for US regulatory agency approval. This approval marks the 46th successful regulatory inspection for QPS India over the past two decades, including previous audits by the US FDA, EMA, UK MHRA, WHO, ANVISA, NPRA, NABL, GCC, and CDSCO, and reinforces QPS India's unwavering commitment to the highest standards of quality, compliance, and scientific rigor.
Article content
Article content
QPS India, a subsidiary of QPS Holdings, LLC (QPS), a GLP/GCP-compliant global full-service Contract Research Organization, has achieved another significant milestone by successfully completing an unscheduled inspection by the US FDA.
Article content
'This outcome underscores QPS India's focus on quality, compliance, and scientific integrity. It comes at the perfect time as we introduce specialized dermal safety services for our global clients. Our team's unwavering efforts continue to position us as a reliable partner for regulatory-driven, high-quality research, said Dr. Kumar Ramu, Sr. Vice President & Managing Director, QPS India.
Article content
State-of-the-Art Facility:
Article content
138-bed clinical unit, with 1,800+ Phase I and BA/BE studies completed
PK/PD studies in patient populations
11 LC/MS/MS instruments for bioanalysis, with 800+ bioanalytical methods developed
Article content
Clinical Services: Phase I to Phase IV studies
Fully compliant with global standards, including ICH-GCP and local regulatory requirements
Dermatology Safety Study Expertise
Skin Irritation (Cumulative Irritation Patch Test – CIPT) studies
Sensitization (Human Repeat Insult Patch Test – HRIPT) studies
Bioanalytical Services: Advanced analysis using cutting-edge technology
Medical Writing: High-quality documentation for regulatory compliance
Clinical Data Management: Efficient handling of clinical data
Pharmacokinetics and Statistical Analysis: Robust statistical models on comparative trials for FDA and EMA submissions
Quality Assurance and Regulatory Support: Proven track record with successful submissions to global regulatory authorities (including FDA and EMA)
Article content
QPS India, established in Hyderabad in 2004, is a subsidiary of QPS Holdings, LLC, a GLP/GCP-compliant global full-service CRO providing discovery, preclinical, bioanalysis, and clinical research services to pharma and biotech clients for the past 30 years. With a robust presence across 9 locations worldwide, including the USA (Delaware – Headquarters, Miami & Missouri), Europe (Austria & The Netherlands), Asia (Taiwan, China & India), and Australia (Melbourne), QPS accelerates pharmaceutical breakthroughs by delivering custom-built research services in Pharmacology, Toxicology, DMPK, Bioanalysis, Translational Medicine, Leukopaks and Cell Therapy Products, Clinical Trials, and Clinical Research Services.
Article content
ABOUT QPS HOLDINGS, LLC
Article content
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO). Over the last 30 years, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees and a robust presence across 9 locations worldwide, including the USA, Europe, Asia, and Australia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, leukopaks and cell therapy products, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. For more information, visit www.qps.com or email info@qps.com.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 days ago
- Cision Canada
BTL Announces Expanded Clearances and Versatility for EMSELLA® Platform
TORONTO, June 5, 2025 /CNW/ -- BTL, a global leader in non-invasive medical solutions, proudly announces expanded Health Canada License for its revolutionary EMSELLA® platform, reinforcing its leadership in pelvic health and intimate wellness. FDA-cleared and Health Canada-licensed for the treatment of urinary incontinence in both men and women, Emsella now also holds an additional Health Canada license and CE-mark certification for enhancing sexual function in patients experiencing somatic sexual arousal disorders caused by weak pelvic floor muscles. Backed by robust clinical outcomes, EMSELLA continues to redefine non-invasive care across pelvic health and sexual function. Key findings include: Sexual Dysfunction Statistics: 76% improvement in sexual satisfaction and desire 1 60% improvement in orgasm quality 1 37% improvement in maintaining erection during intercourse 2 48% improvement in pelvic muscle endurance 3 When compared to other modalities, EMSELLA outperforms significantly: 7x more effective than pelvic floor muscle training "EMSELLA continues to surpass expectations—not just in treating incontinence but in restoring confidence, and overall quality of life," said David Chmel, CEO of BTL North America. "These expanded clearances and clinical outcomes validate what providers and patients have long experienced: EMSELLA delivers meaningful results in a way that's accessible, comfortable, and non-invasive." Shari Caplan, MD, CCFP, FCFP, FAARM, a board-certified expert in functional, integrative , anti-aging, and intimate health said, "We're witnessing a complete shift in how pelvic and sexual health is approached. Patients are achieving results we used to think were only possible with surgery or years of therapy. EMSELLA has become a go-to solution in my practice for urinary control and sexual wellness for both men and women." As the demand for intimate wellness treatments rises, EMSELLA remains uniquely positioned as an effective and versatile tool for addressing some of the most intimate and often under-discussed health concerns. To learn more about EMSELLA, visit About BTL Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 350+ patents and over 580 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes , EMSCULPT NEO®, EMFACE®, EXION™, EXOMIND™, EMSELLA®, and others. For more information, visit
Cision Canada
3 days ago
- Cision Canada
Jiva Technologies First Purchase Order of LIV3's SugarShield Supplement Is Ready to Ship from Best Formulations and Will Begin Shipping Direct to Consumers by June 10, 2025
VANCOUVER, BC, June 5, 2025 /CNW/ -- Jiva Technologies (CSE: JIVA) (Frankfurt: WNT1) (OTCQB: PLTXF) ("JIVA" or the "Company"), a leader in building niche online wellness communities and creating immersive physical environments, is pleased to announce that the first commercial production run of LIV3's SugarShield supplement is ready to ship from Best Formulations, a Sirio Group company. Fulfillment to consumers will begin on June 10, 2025, with pre-sale orders placed since the website's January launch transitioning to active shipping and standard orders opening thereafter. Best Formulations, a Sirio Group company renowned for producing some of the most recognized supplements in the United States, brings unparalleled expertise and quality assurance to this project. LIV3's SugarShield capsules feature a liposomal delivery system designed to enhance nutrient absorption and bioavailability, with benefits expected to be felt within as little as two weeks. Jiva believes that the e-commerce supplements category continues to expand rapidly, driven by increasing consumer demand for functional, science-backed products that support targeted wellness goals—from metabolic health to cognitive performance. The segment has seen significant growth as consumers prioritize convenience and transparency, with direct-to-consumer brands leading the charge. Lorne Rapkin, CEO of Jiva Technologies, commented: " is without question one of my favorite websites we've built at Jiva. I've been closely following the surge of new supplement brands launching GLP-1-inspired formulations and other wellness-forward solutions, and it's clear the world is ready for products that support better health outcomes in accessible ways. I believe that supplements are the fastest growing category in e-commerce right now, and partnering with Chris Mearns to launch SugarShield and oversee the entire digital strategy is a critical part of our vision to make wellness more attainable for everyone. I genuinely cannot wait for people to hold these jars in their hands and experience the results for themselves." This marks another milestone in Jiva's expanding portfolio of wellness-focused ventures, as the Company continues to leverage its digital expertise and consumer insights to build brands that connect with today's health-conscious audience. For more information about LIV3 or SugarShield, please visit About JIVA Technologies JIVA Technologies is dedicated to building niche online wellness communities and creating immersive physical environments. With a proven track record in e-commerce marketplaces, bolstered by expert UI/UX design and SEO, JIVA now focuses on joint ventures to support wellness brands in developing their online presence. The company owns and operates Bloombox Club, an online plant delivery marketplace serving the United States, Germany, the United Kingdom, Austria, the Republic of Ireland, France, Spain, and Italy, as well as The Locavore Bar and Grill, a vibrant dining and gathering destination in Squamish, BC. Recently, JIVA became a shareholder in VEG House, a leader in the plant-based space, through a share exchange agreement. Committed to e-commerce, marketing, and wellness, JIVA's mission is to cultivate online communities of like-minded consumers through education and collaboration. The company is actively pursuing joint ventures, such as the recently announced partnership with LIV3 for SugarShield, to empower wellness brands online by building their websites and managing all digital marketing. About LIV3 LIV3 is dedicated to improving metabolic health by addressing the detrimental effects of fructose through its flagship product, SugarShield. Originally introduced through where the product received overwhelmingly positive feedback for its efficacy, SugarShield features Luteolin, a powerful compound that blocks fructokinase. SugarShield has the potential to reduce cravings, boost energy, and support weight management by preventing fructose metabolism. This innovative approach allows individuals to experience the benefits of a sugar-free lifestyle without making drastic dietary changes. Backed by research, LIV3's solution targets the suspected root cause of metabolic dysfunction and offers a natural, effective way to improve overall health and wellness. About Best Formulations (a Sirio Company) Best Formulations, a Sirio Company, is a leading U.S.-based contract manufacturer specializing in high-quality dietary supplements, over-the-counter drugs, and functional foods. As part of the global Sirio Group—a renowned leader in the nutraceutical industry—Best Formulations combines international expertise with state-of-the-art manufacturing facilities in the United States. Committed to excellence and stringent quality control, the company adheres to strict U.S. regulatory standards and Good Manufacturing Practices (GMP), ensuring that products like SugarShield are manufactured to the highest quality. With over 35 years of industry experience, Best Formulations is dedicated to being a trusted partner in bringing innovative health products to market both domestically and internationally. Contact Lorne Rapkin Chief Executive Officer (416) 419-1415 Forward-looking Information This press release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as "may," "will," "expect," "likely", "should," "would," "plan," "anticipate," "intend," "potential," "proposed," "estimate," "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussions of strategy. The forward-looking information contained herein includes, without limitation, statements regarding the availability of Future Farm products, JIVA promotional events and the business and strategic plans of the Company. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: receiving sufficient demand for the Offering; the Company's ability to comply with all applicable governmental regulations including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; the conflict in eastern Europe; having a limited operating history; the ability of the Company to access capital to meet future financing needs; the Company's reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions. Additional risk factors can also be found in the Company's continuous disclosure documents, which have been filed on SEDAR and can be accessed at Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained applicable herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by law.
Globe and Mail
5 days ago
- Globe and Mail
Why Guardant Health Stock Surged Nearly 9% Higher Today
Precision oncology specialist Guardant Health (NASDAQ: GH) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped almost 9% higher today. This made it quite the outperformer on the exchange, as the bellwether S&P 500 index's gain was a relatively modest 0.6%. A new designation This morning before market open, Guardant announced that the U.S. Food and Drug Administration (FDA) had granted the healthcare company's Shield multi-cancer detection (MCD) test its Breakthrough Device designation. This instantly confers a high status on Shield, as the FDA's designation is given only to a small clutch of medical devices that can either diagnose or treat a disease more effectively than other products. In Shield's case, it is quite a versatile diagnostic device that can screen for a wide range of cancers, including colorectal, lung, and ovarian. It is designed to evaluate people 45 years of age or older who are at a typical average risk for cancer. According to Guardant, Shield has 98.6% specificity and 75% sensitivity in detecting certain cancers. In its news release touting the FDA's move, Guardant quoted its co-CEO AmirAli Talasaz as saying that it "shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw." "We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly," he added. Coming to market soon Another big plus of the Breakthrough Device designation is that it's part of an FDA initiative aimed at getting useful medical products to market faster. Talasaz and his team at Guardant might just get their wish with Shield before long. Should you invest $1,000 in Guardant Health right now? Before you buy stock in Guardant Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Guardant Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor 's total average return is987% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
